[go: up one dir, main page]

WO1992002640A1 - Recepteur de cannabinoides - Google Patents

Recepteur de cannabinoides Download PDF

Info

Publication number
WO1992002640A1
WO1992002640A1 PCT/US1991/005656 US9105656W WO9202640A1 WO 1992002640 A1 WO1992002640 A1 WO 1992002640A1 US 9105656 W US9105656 W US 9105656W WO 9202640 A1 WO9202640 A1 WO 9202640A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
cannabinoid receptor
cannabinoid
protein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/005656
Other languages
English (en)
Inventor
Lisa A. Matsuda
Michael J. Brownstein
Tom I. Bonner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Commerce
US Department of Health and Human Services
Original Assignee
United States Department of Commerce
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Commerce, US Department of Health and Human Services filed Critical United States Department of Commerce
Priority to JP91515626A priority Critical patent/JPH05507417A/ja
Publication of WO1992002640A1 publication Critical patent/WO1992002640A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention relates to a DNA segment encoding a mammalian cannabinoid receptor, the cannabinoid receptor encoded therein and recombinantly produced cannabinoid receptor protein.
  • Cannabinoids are the primary active constituents of marijuana, a preparation of the plant Cannabis Sativa , producing prominent effects on the central nervous system. They are responsible for effects such as changes in mood, perception, cognition, memory and psychomotor skills. Cannabinoids, well known for their psychoactivity, also have value as therapeutic agents. Cannabinoids have found use in the treatment of chemotherapy side effects, glaucoma, bronchial asthma and insomnia. They can also be used as analgesics, muscle relaxants or anticonvulsants.
  • cannabinoid action is that these drugs may be active at a specific neurotransmitter receptor site. This hypothesis is supported by the fact that the behavior of the drugs is dose dependent, pharma ⁇ cologically selective and stereospecific in man as well as a variety of animal idels. However, prior to the present invention, the structure of such a cannabinoid receptor was not known.
  • the present invention relates to a DNA segment encoding all, or a unique portion, of a mammalian cannabinoid receptor, or a DNA fragment comple ⁇ mentary to the DNA segment.
  • the present invention relates to a cannabinoid receptor protein substantially free of proteins with which it is normally associated. Further, the present invention relates to a recombinantly produced protein having all, or a unique portion of the amino acid sequence given in Figure 1 or Figure 5.
  • the present invention relates to a recombinant DNA molecule comprising the DNA segment encoding all, or a unique portion, of a mammalian cannabinoid receptor, or a DNA fragment complementary to the DNA segment and a vector.
  • the present invention also relates to a host cell stably transformed with the above- described recombinant DNA molecule in a manner allowing expression.
  • the present invention relates to a method of producing a recombinant cannabinoid receptor comprising culturing host cells of the present invention, in a manner allowing expression of the receptor and isolating the receptor.
  • the present invention relates to a method of screening compounds for their ability to bind to the recombinant cannabinoid receptor of the present invention comprising contacting the receptor with the compound under conditions such that binding can be effected and detecting the presence or absence of binding.
  • the present invention relates to a method of detecting cannabinoids or cannabinoid-like compounds in a biological sample compris ⁇ ing contacting the recombinant cannabinoid receptor of the present invention with the biological sample under condi ⁇ tions such that binding can be effected and detecting the presence or absence of binding.
  • the present invention relates to a method of identifying and isolating biomolecules which naturally interact with the cannabinoid receptor comprising contacting the recombinant receptor cannabinoid receptor of the present invention with a biological sample under conditions such that binding can be effected and detecting the presence or absence of binding.
  • the present invention relates to an assay for detection of cannabinoid receptor in tissue comprising contacting the tissue with the antibody of the present invention specific for the receptor and detecting the presence or absence of a complex formed between the antibodies and proteins present in the tissue.
  • Figure 1 shows the partial nucleotide sequence of SKR6 cDNA. Indicated above and below the sequence, respectively, are the predicted hydrophobic domains (I through VII) and the translated primary structure of the receptor. The initial stretch of guanine nucleotides represents the G tail produced during cDNA synthesis.
  • the substance K receptor derived probe sequence is indicated by dots (bases identical to SKR6) beginn i ng at base number 449; non-identical bases are provide, above the cDNA sequence and a single nucleotide gap (hyphen) has been introduced to align the probe with the cDNA sequence. Underlined amino acids are those which are highly con ⁇ served among other G protein-coupled receptors.
  • Figure 2 shows the results of a northern blot analysis of total RNAs from N18TG-2 (lane a) , NG108-15 (lane b) and C6BU-1 (lane c) cell lines.
  • N18TG-2 and C6BU-1 cells are the neuroblastoma (mouse) and glioma (rat) parents of the NG108-15 hybrid cell line, respec ⁇ tively.
  • the single hybridizing band present in lanes a and b is ca. 6.0 kb.
  • Figure 3 shows the localization of SKR6 mRNA in rat brain.
  • Cx cerebral cortex
  • DG dentate gyrus
  • Hi hippocampus
  • VMH ventromedial hypothalamic nucleus.
  • Figures 4a and 4b show cannabinoid-induced inhibition of forskolin-stimulated cAMP production in SKR6-trans- fected CHO-K1 cells.
  • Fig. 4a shows stereospecific inhibi ⁇ tion by d9THC.
  • Fig. 4b shows the dose-response curves of various cannabinoids and cannabinoid analogs. Data represent the average percent inhibition + Standard Error of the Mean (S.E.M.) of cAMP accumulation for 3-5 experi ⁇ ments each performed in triplicate. Curves were generated using Graph-Pad InPlot regression analysis program.
  • Figure 5 shows the partial nucleotide sequence of the human cannabinoid receptor gene. Indicated below is the deduced amino acid sequence of the receptor.
  • the present invention relates to a DNA sequence encoding all, or a unique portion, of a mammalian cannabinoid receptor and to the protein (or polypeptide) encoded therein, or allelic variations thereof.
  • a "unique portion” as used herein is defined as consisting of at least five (or six) amino acids or correspondingly, at least 15 (or 18) nucleotides.
  • the invention also relates to recombinant molecules containing such DNA segments and to cells transformed therewith.
  • the present invention relates to DNA segments that encode the entire amino acid sequence given in Figure 1 or Figure 5 (the specific DNA segments given in Figure 1 and Figure 5 being only two such exam- pie) i or any unique portion thereof.
  • DNA segments to which the invention relates also include those encoding substantially the same receptor as that of Figure 1 or Figure 5 which includes, for example, allelic forms of the Figure 1 or Figure 5 amino acid sequence.
  • the invention also relates to DNA fragments complementary to such sequences. A unique portion of the DNA segment or the complementary fragment thereof of the present invention can be used as probes for detecting the presence of its complementary strand in a DNA or RNA sample.
  • the present invention relates to a ribonucleotide segment (that is, a riboprobe) which encodes the entire amino acid sequence given in Figure 1 or Figure 5, or any unique portion thereof.
  • a ribonucleotide segment that is, a riboprobe
  • the riboprobes of the present invention can be used to detect the presence of its complementary strand of DNA or RNA in a sample.
  • the present invention relates to a cannabinoid receptor protein substantially free of proteins with which it is normally associated. (One skilled in the art can easily purify the cannabinoid receptor protein using standard methodologies for protein purification.)
  • the present invention also relates to peptide fragments unique to the cannabinoid receptor.
  • the protein and/or peptides of the present invention may be chemically synthesized using known methods.
  • the present invention relates to a recombinantly produced or chemically synthe- sized cannabinoid receptor with the amino acid sequence given in Figure 1, Figure 5 or an allelic variation thereof.
  • the receptor has several potential N-linked glycosylation sites. Accordingly, the recombinantly produced protein may be unglycosylated or glycosylated (the glycosylation pattern may differ from that of the naturally occurring receptor) .
  • the present invention further relates to proteins having amino acid sequences sufficiently similar to that given in Figure l or Figure 5 to afford the binding characteristics as the naturally occurring molecule.
  • the present invention relates to a recombinant DNA molecule and to a host cell transformed therewith.
  • a recombinant DNA molecule comprising a DNA segment encoding all or a unique portion of the mammalian cannabinoid receptor of the present invention and a vector can be constructed.
  • Possible vectors for use in the present invention include, but are not limited to, Okayama-Berg pCDl mammalian vector, ptk-muARS or pAcY l(baculovirus) and pGEX-3X(GST gene fusion system) .
  • the DNA segment can be present in the vector operably linked to regulatory elements, including, for example, a promoter.
  • Suitable host cells can be transformed with the recombinant molecule using standard methods well known in the art.
  • Possible host cells include eukaryotic cells such as CHO-K1 (ATCC accession member CCL 61) , mouse L cells or Sf9 (Spodoptera frugiperda) and yeast (schizo- saccharomyces pombe) and prokaryotic cells such as E. coli(JMlOl) , which are all publically available.
  • the present invention relates to antibodies specific for the cannabinoid recep ⁇ tor of the present invention.
  • the present invention relates to a method of screening compounds for their ability to bind to the recombinant cannabinoid receptor of the present invention.
  • Drugs which bind to the receptor may be useful in the treatment of cannabinoid-treatable conditions.
  • New drugs lacking the legal complications associated with marijuana, for treating, reversing or eliminating conditions such as chemotherapy side effects, glaucoma, bronchial asthma, insomnia, eating di ⁇ .>... ers and/or weight problems can be identified by contacting the receptor with a compound under conditions such that binding can be effected. The presence or absence of bound compound to receptor is then detected using methods well known in the art.
  • the present invention relates to a method of detecting cannabinoids or cannabinoid-like compounds (that is, exogeneous sub ⁇ stances) in a biological sample.
  • the presence or absence of the compound can be determined by contacting the recombinant cannabinoid receptor of the present invention with a biological sample such as for example, tissue extracts, cerebrospinal fluid, blood, urine or other body fluids, under conditions such that binding between a drug with the receptor can be effected and detecting the presence or absence of bound drug to the receptor using methods well known in the art.
  • This method can be incorporated into drug testing programs such as those used by companies and athletics clubs.
  • the present invention relates to a method of identifying and isolating natural biomolecules (such as, a neurotransmitter, hormone or peptide) which naturally interacts with the receptor in the body (that is, an endogeneous ligand) .
  • the receptor's natural ligand can be identified and isolated by contact- ing the recombinant cannabinoid receptor of the present invention with a biological sample under conditions such that binding can be effected.
  • the presence of a bound biomolecule can then be detected and identified using methods well known in the art.
  • the present invention relates to an assay for detection of the cannabinoid receptor in tissue. The presence or absence of the receptor can be determined by contacting the tissue with an antibody specific for the receptor and detecting formation of antibody-receptor complex.
  • EXAMPLE ISOLATION OF RAT RECEPTOR GENE SKR6 was isolated from a rat cerebral cortex cDNA library constructed in the mammalian expression vector pCDl as described by Okayama et al. [Mol. Cell. Biol. , 3: 280-289 (1983)]. Screening was performed as described previously for cloning muscarinic receptor subtype cDNAs [Bonner et al., Science, 237: 527-532 (1984)]. Sequencing was performed by dideoxynucleotide-chain termination of single-stranded DNA obtained from restriction fragments inserted into M13 mpl8 or 19 [Yanisch-Perron, Gene, 33: 103 (1985)]. The deduced amino acid sequence, shown in Figure
  • the probe sequence was derived from the sequence of the substance K receptor, however, less than 25% homology overall exists between the amino acid sequence of SKR6 and the substance K receptor. Although characteristic of the G protein-coupled class of membrane-located receptors, the amino acid sequence of SKR6 is not obviously similar to that of the substance K receptor nor any other receptor cloned to date.
  • LH-CG receptor (lacks the corresponding proline [McFarland et al., Science, 245: 494-499 (1989) and Loosfelt et al.,
  • SKR6 N-linked glycosylation sites are enclosed within boxes.
  • the entire SKR6 cDNA (5.7 kb) includes an additional circa 4100 bases 3' of the given sequence.
  • SKR14 a second clone was isolated whose coding region, although incomplete, was identical to SKR6.
  • the 3' untranslated sequence of SKR14 was circa 2900 bases shorter than that of SKR6. Comparison of the sequences of these clones indicates that SKR14 is the product of an alternatively poly-adenylated mRNA.
  • RNAs were isolated from cultured N18TG-2, NG108-15 and C6BU-1 cells using the guanidinium thiocyanate method as described by Chomczynski et al. [Anal. Biochem., 162: 156-159 (1987)], and loaded (lO ⁇ g/lane) into a 1% aga ⁇ rose/formaldehyde gel. Following electrophoresis and electrotransfer the filter was hybridized to a nick- translated fragment of the SKR6 cDNA, washed (0.1 x SSPE/0.1% SDS, 60°C) and exposed to x-ray sensitive film for 6 days (-80°C) (see Figure 2) .
  • SKR6 As a cannabinoid receptor, other ligands were tried such as neurotensin, d-ala-d-leu enkephalin, various adenosine analogs, somatostatin, bradykinin, secretion and PGE.
  • the recep ⁇ tors for these had all been described in either N18TG-2 or NG108-15 cells [Howlett et al., Mol. Pharmcol., 26: 532- 538 (1984) and Nirenburg et al. , Science, 222: 794-799 (1983)].
  • Transfection and selection of cells were performed as described [Chen et al. , Mol. Cell. Biol., 7: 2745-2752 (1987) ] .
  • a monoclonal line expressing the SKR6 cDNA was obtained by limiting-dilution cloning of cells expressing the corresponding mRNA as determined by Northern blot analysis. Functional expression studies were similar to experiments designed by Howlett et al. [Howlett et al., Mol. Pharmacol., 29: 307-313 (1986)].
  • Transfected cells were resuspended (1.25 x 10 6 cells/ml) in culture media containing fatty-acid free BSA (0.25%). Cells were incubated (37°C) for five min.
  • EC 50 values mean nM ⁇ Standard Error of the Mean (S.E.M.) for the inhibition of stimulated cAMP accumulation were 13.5 ⁇ 2.7 for (-)d9THC, 773 ⁇ 187 for (+) d9THC, 0.87 ⁇ 0.20 for CP 55940, 8.9 ⁇ 1.8 for 11-OH d9THC and 16.6 ⁇ 4.9 for nabilone.
  • CP 55940 and nabilone are synthesized by Pfizer and Lilly Research laboratories, respectively. other cannabinoics are compounds distributed by the National Institute of Drug Abuse.
  • CHO cells were transfected with an ⁇ - adrenergic receptor, a muscarinic receptor or SKR6.
  • ⁇ -adrenergic receptor a muscarinic receptor or SKR6.
  • Both the ⁇ -adrenergic nor muscarinic receptors responded to (-) ⁇ 9THC or CP 55940 (see Table I below) . Both these receptors, however, reduced cAMP production in response to their respective agonists.
  • both the muscarinic and adrenergic receptors are Gi-coupled, the cannabinoid-induced inhibition of adenylate cyclase activity observed in SKR6-transfected cells was not due to the interaction of cannabinoids with this class of recep ⁇ tors and was clearly specified to SKR6. TABLE I
  • Values represent the average accumulation of cAMP + S.E.M. as percent of forskolin-stimulated controls.
  • the effects of the various agonists were examined in 3-5 experiments (each performed in triplicate) .
  • Numbers in parentheses are the absolute values of cAMP as deter ⁇ mined by RIA (p oles cAMP/10 6 cells/5 min) .
  • Final concen- trations of forskolin were 500 nM for all cell lines except NG108-15; forskolin concentration for this cell line was 250 nM.
  • the muscarinic and adrenergic receptor- transfected cells were assayed under conditions identical to those routinely used to test the SKR6-transfected cells (see figure 3) .
  • Final concentrations of carbachol (ago ⁇ nist for muscarinic receptors) and clonidine (agonist for ⁇ -adrenergic receptors) were 100 ⁇ M and 10 ⁇ M, respec ⁇ tively.
  • carbachol ago ⁇ nist for muscarinic receptors
  • clonidine agonist for ⁇ -adrenergic receptors
  • a human cosmid library purchased from Stratagene [(catalog no. 951-202)], was screened with a probe specific for the rat cannabinoid receptor.
  • the probe con- stituted of EcoRV-Xbal SKR6 restriction fragment corre ⁇ sponding to bases 97 to 1370 of Figure 1.
  • a positive clone was sequenced as described for the rat cDNA clone.
  • the partial nucleotide sequence of the DNA and deduced amino acid sequence are shown in Figure 5. There is about 97% homology between the deduced amino acid sequence of the human receptor and the rat receptor.
  • the human cannabinoid receptor gene was inserted into a ptk-muARS vector [Hoist et al.. Cell, 52: 355-365 (1988) and Zastrow et al., Nucl. Acid Res., 17: 1867-1879 (1989)].
  • the recombinant molecule was then transfected into L-M(tk-) L cells (American Type Culture Collection Accession number ATCC CCL 1.3) by methods which are reproducible and known in the art. Expression of the receptor protein was detected using described methods [Devane et al., Mol. Pharmacol., 34: 605-613 (1988)]. This stably transformed cell line enables binding assays to be preformed on immortal tissue culture cells.
  • This cell line is unique in that the same cell line exists without the cannabinoid receptor (non- transfected L-cells) and thus can be used to demonstrate ligand-receptor interactions which are specific to the cannabinoid receptor.
  • Some cannabinoid receptor assays can be performed on tissue preparations, but without antagonist ligands (none currently available) , demonstra ⁇ tions of specificity are limited (particularly in assays which measure a functional response) .
  • This cell line expresses approximately 10 fold more cannabinoid receptor mRNA than the neuroblastoma cell line, N18TG-2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Rectifiers (AREA)

Abstract

La présente invention concerne un segment d'ADN codant pour un récepteur de cannabinoïdes chez les mammifères et la protéine codée dans ce récepteur. Ladite invention concerne également une molécule d'ADN recombiné codant pour le récepteur dans des cellules hôtes transfectées avec ladite molécule et une protéine de récepteur produite par recombinaison.
PCT/US1991/005656 1990-08-08 1991-08-08 Recepteur de cannabinoides Ceased WO1992002640A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP91515626A JPH05507417A (ja) 1990-08-08 1991-08-08 カンナビノイド受容体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56407590A 1990-08-08 1990-08-08
US564,075 1990-08-08

Publications (1)

Publication Number Publication Date
WO1992002640A1 true WO1992002640A1 (fr) 1992-02-20

Family

ID=24253065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/005656 Ceased WO1992002640A1 (fr) 1990-08-08 1991-08-08 Recepteur de cannabinoides

Country Status (5)

Country Link
EP (1) EP0542920A4 (fr)
JP (1) JPH05507417A (fr)
AU (1) AU645609B2 (fr)
CA (1) CA2087844A1 (fr)
WO (1) WO1992002640A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025589A1 (fr) * 1993-04-27 1994-11-10 Medical Research Council Recepteur des cannabinoïdes exprime dans les cellules du systeme immunitaire
US5671547A (en) * 1993-12-30 1997-09-30 Seb S.A. Hair dressing accessory for a hair dryer appliance
WO2002000712A1 (fr) * 2000-05-16 2002-01-03 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, recepteur cannabinoide central humain 22, et polynucleotide codant ce polypeptide
WO2004008150A1 (fr) * 2002-07-17 2004-01-22 Astrazeneca Ab Procedes permettant d'identifier des antagonistes vrais et des agonistes inverses du recepteur cannabinoide
WO2004007551A1 (fr) * 2002-07-17 2004-01-22 Astrazeneca Ab Variante d'epissage du recepteur cannabinoide (cb1b)
WO2001079439A3 (fr) * 2000-03-29 2004-04-08 Biowindow Gene Dev Inc Nouveau polypeptide, proteine humaine de reception cannabinoide 19, et un polynucleotide codant pour ce polypeptide
EP2722669A1 (fr) 2012-10-22 2014-04-23 Securetec Detektions-Systeme AG Procédé et dispositif destinés à la vérification de drogues illégales
WO2020232350A1 (fr) * 2019-05-15 2020-11-19 The Regents Of The University Of Colorado, A Body Corporate Dosages pour cannabinoïdes synthétiques
WO2024022478A1 (fr) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 Anticorps se liant au récepteur cannabinoïde cb1 et son utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01273582A (ja) * 1988-04-26 1989-11-01 Matsushita Electric Ind Co Ltd モノクローナル抗体産生細胞ライン及びモノクローナル抗体及び免疫原
JPH068399B2 (ja) * 1988-08-10 1994-02-02 東洋製罐株式会社 製缶用塗料
JPH0257178A (ja) * 1988-08-22 1990-02-26 Matsushita Electric Ind Co Ltd モノクローナル抗体産生細胞ラインおよびモノクローナル抗体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Nature, Volume 346, issued 09 August 1990, MATSUDA et al., "Structure of a Cannabinoid Receptor and Functional Expression of the cloned cDNA", pages 561-564, see Abstract, figure 1. *
Nucleic Acids Research, Volume 18, No. 23, issued 1990, GERARD et al., "Nucleotide sequence of a human Cannabinoid receptor cDNA", page 7142, see entire article. *
Science, Volume 237, issued 31 July 1987, BONNER et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", pages 527-532, see Abstract. *
See also references of EP0542920A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025589A1 (fr) * 1993-04-27 1994-11-10 Medical Research Council Recepteur des cannabinoïdes exprime dans les cellules du systeme immunitaire
US5671547A (en) * 1993-12-30 1997-09-30 Seb S.A. Hair dressing accessory for a hair dryer appliance
WO2001079439A3 (fr) * 2000-03-29 2004-04-08 Biowindow Gene Dev Inc Nouveau polypeptide, proteine humaine de reception cannabinoide 19, et un polynucleotide codant pour ce polypeptide
WO2002000712A1 (fr) * 2000-05-16 2002-01-03 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, recepteur cannabinoide central humain 22, et polynucleotide codant ce polypeptide
WO2004008150A1 (fr) * 2002-07-17 2004-01-22 Astrazeneca Ab Procedes permettant d'identifier des antagonistes vrais et des agonistes inverses du recepteur cannabinoide
WO2004007551A1 (fr) * 2002-07-17 2004-01-22 Astrazeneca Ab Variante d'epissage du recepteur cannabinoide (cb1b)
EP2722669A1 (fr) 2012-10-22 2014-04-23 Securetec Detektions-Systeme AG Procédé et dispositif destinés à la vérification de drogues illégales
WO2014064046A1 (fr) 2012-10-22 2014-05-01 Securetec Detektions-Systeme Ag Procédé et dispositif de détection de drogues illicites
WO2020232350A1 (fr) * 2019-05-15 2020-11-19 The Regents Of The University Of Colorado, A Body Corporate Dosages pour cannabinoïdes synthétiques
WO2024022478A1 (fr) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 Anticorps se liant au récepteur cannabinoïde cb1 et son utilisation

Also Published As

Publication number Publication date
EP0542920A4 (en) 1993-07-14
AU645609B2 (en) 1994-01-20
CA2087844A1 (fr) 1992-02-09
JPH05507417A (ja) 1993-10-28
EP0542920A1 (fr) 1993-05-26
AU8543091A (en) 1992-03-02

Similar Documents

Publication Publication Date Title
Weinshank et al. Cloning, expression, and pharmacological characterization of a human alpha 2B-adrenergic receptor.
AU777247B2 (en) DNA encoding SNORF25 receptor
JP4216326B2 (ja) ヒト神経ペプチドｙ／ペプチドｙｙ／膵臓ポリペプチド受容体（ｙ４）をコードしたｄｎａ、及び該ｄｎａの使用
JP3018045B2 (ja) ドーパミンリセプター及び遺伝子
AU652349B2 (en) Glutamate receptor compositions and methods
US5288607A (en) Polypeptides having a β-adrenergic receptor activity in man, implicated in the lipolytic response, nucleic acids coding for these polypeptides and the use of these polypeptides for the screening of a substance active on these polypeptides
Nash et al. Cloning and characterization of the opossum kidney cell D1 dopamine receptor: expression of identical D1A and D1B dopamine receptor mRNAs in opossum kidney and brain.
EP1319070A2 (fr) Genes de recepteurs mammaliens et leurs utilisations
EP0832230B1 (fr) Compositions destinees au recepteur neuronal humain de l'acetylcholine nicotinique et leurs procedes d'utilisation
JP2002512779A (ja) 新規なｇ−タンパク質共役型受容体
AU645609B2 (en) Cannabinoid receptor
US5789196A (en) Recombinantly produced β4 neuronal nicotinic acetylcholine receptor subunits
US7510846B2 (en) Assay employing human or rat GAL-R2 galanin receptor
COHEN et al. Characterization of a mouse β1-adrenergic receptor genomic clone
US20090226436A1 (en) Novel receptors
WO2002042458A2 (fr) Nouveaux recepteurs
US6432652B1 (en) Methods of screening modulators of opioid receptor activity
JP2001500389A (ja) 選択的ａｔｐ親和性を示すｇ―結合レセプター
US5449606A (en) DNA encoding neuronal nicotinic acetylcholine receptor compositions containing the beta 4 subunit
KR100977824B1 (ko) Ｅｐｆ 수용체 에세이, 화합물 및 치료학적 조성물
Miotto et al. Molecular characterization of opioid receptors
CA2290713A1 (fr) Homologue du recepteur edg-6 humain
US7381542B2 (en) Nucleic acids encoding a biogenic amine receptor
Stadel et al. Molecular Biology of ẞ-Adrenoceptors
US20030045685A1 (en) Novel receptors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991917229

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2087844

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991917229

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991917229

Country of ref document: EP